Aprea Therapeutics’ (APRE) “Outperform” Rating Reiterated at Wedbush

Wedbush reissued their outperform rating on shares of Aprea Therapeutics (NASDAQ:APRE) in a research report sent to investors on Tuesday,RTT News reports. They currently have a $11.00 price target on the stock. Wedbush also issued estimates for Aprea Therapeutics’ FY2029 earnings at $2.19 EPS.

Separately, HC Wainwright restated a “buy” rating and issued a $20.00 target price on shares of Aprea Therapeutics in a research note on Wednesday, January 15th.

Aprea Therapeutics Trading Down 1.8 %

Shares of NASDAQ:APRE opened at $2.20 on Tuesday. The stock has a market cap of $11.96 million, a PE ratio of -0.78 and a beta of 0.82. The stock’s fifty day simple moving average is $3.06 and its two-hundred day simple moving average is $3.24. Aprea Therapeutics has a 1-year low of $2.15 and a 1-year high of $6.80.

Aprea Therapeutics (NASDAQ:APRE) last released its quarterly earnings results on Tuesday, March 25th. The company reported ($0.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.20. Aprea Therapeutics had a negative net margin of 1,029.50% and a negative return on equity of 57.86%. The company had revenue of $0.21 million for the quarter, compared to analyst estimates of $0.15 million. On average, sell-side analysts forecast that Aprea Therapeutics will post -2.55 earnings per share for the current fiscal year.

Institutional Trading of Aprea Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets purchased a new stake in Aprea Therapeutics in the fourth quarter worth $43,000. LPL Financial LLC bought a new position in shares of Aprea Therapeutics during the 4th quarter worth $53,000. Landscape Capital Management L.L.C. purchased a new stake in Aprea Therapeutics in the 4th quarter worth about $116,000. Finally, Stonepine Capital Management LLC raised its stake in Aprea Therapeutics by 8.8% in the 4th quarter. Stonepine Capital Management LLC now owns 149,221 shares of the company’s stock valued at $491,000 after acquiring an additional 12,047 shares during the period. Hedge funds and other institutional investors own 34.19% of the company’s stock.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.